{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["He Y"],"funding":["NCI NIH HHS"],"pagination":["e2300688"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10964211"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["12(24)"],"pubmed_abstract":["Stimulator of interferon genes (STING) signaling is a promising target in cancer immunotherapy, with many ongoing clinical studies in combination with immune checkpoint blockade (ICB). Existing STING-based therapies largely focus on activating CD8<sup>+</sup> T cell or NK cell-mediated cytotoxicity, while the role of CD4<sup>+</sup> T cells in STING signaling has yet to be extensively studied in vivo. Here, a distinct CD4-mediated, protein-based combination therapy of STING and ICB as an in situ vaccine, is reported. The treatment eliminates subcutaneous MC38 and YUMM1.7 tumors in 70-100% of mice and protected all cured mice against rechallenge. Mechanistic studies reveal a robust T<sub>H</sub> 1 polarization and suppression of T<sub>reg</sub> of CD4<sup>+</sup> T cells, followed by an eff"],"journal":["Advanced healthcare materials"],"pubmed_title":["STING Protein-Based In Situ Vaccine Synergizes CD4<sup>+</sup> T, CD8<sup>+</sup> T, and NK Cells for Tumor Eradication."],"pmcid":["PMC10964211"],"funding_grant_id":["P30 CA014051","F99 CA274651","R01 CA235375"],"pubmed_authors":["Huang S","Belcher AM","He Y","Kaskow JA","Covarrubias G","Pires IS","Sacane JC","Hammond PT","Hong C"],"additional_accession":[]},"is_claimable":false,"name":"STING Protein-Based In Situ Vaccine Synergizes CD4<sup>+</sup> T, CD8<sup>+</sup> T, and NK Cells for Tumor Eradication.","description":"Stimulator of interferon genes (STING) signaling is a promising target in cancer immunotherapy, with many ongoing clinical studies in combination with immune checkpoint blockade (ICB). Existing STING-based therapies largely focus on activating CD8<sup>+</sup> T cell or NK cell-mediated cytotoxicity, while the role of CD4<sup>+</sup> T cells in STING signaling has yet to be extensively studied in vivo. Here, a distinct CD4-mediated, protein-based combination therapy of STING and ICB as an in situ vaccine, is reported. The treatment eliminates subcutaneous MC38 and YUMM1.7 tumors in 70-100% of mice and protected all cured mice against rechallenge. Mechanistic studies reveal a robust T<sub>H</sub> 1 polarization and suppression of T<sub>reg</sub> of CD4<sup>+</sup> T cells, followed by an eff","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Sep","modification":"2026-07-15T04:40:10.704Z","creation":"2025-08-27T03:08:31.303Z"},"accession":"S-EPMC10964211","cross_references":{"pubmed":["37015729"],"doi":["10.1002/adhm.202300688"]}}